Covered recipient · General Payments record
AMEETH VEDRE
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,598.59
74 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,579.03 | 73 |
| Education | $19.56 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $298.86 | 16 |
| Amgen Inc. | $241.04 | 14 |
| Merck Sharp & Dohme LLC | $186.89 | 6 |
| PFIZER INC. | $169.89 | 8 |
| Abbott Laboratories | $121.70 | 1 |
| Alnylam Pharmaceuticals Inc. | $89.93 | 4 |
| Kiniksa Pharmaceuticals International, plc | $72.48 | 4 |
| AstraZeneca Pharmaceuticals LP | $65.79 | 4 |
| E.R. Squibb & Sons, L.L.C. | $48.42 | 3 |
| SCPHARMACEUTICALS INC. | $38.04 | 1 |
| Esperion Therapeutics, Inc. | $34.63 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.58 | 1 |
| Philips North America LLC | $28.33 | 1 |
| CVRx, Inc. | $27.54 | 1 |
| Janssen Pharmaceuticals, Inc | $25.37 | 1 |
| Edwards Lifesciences Corporation | $20.60 | 1 |
| Novo Nordisk Inc | $20.05 | 1 |
| Medtronic, Inc. | $17.77 | 1 |
| Lexicon Pharmaceuticals, Inc. | $16.88 | 1 |
| Vifor Pharma, Inc. | $16.08 | 1 |
| Actelion Pharmaceuticals US, Inc. | $15.53 | 1 |
| SANOFI-AVENTIS U.S. LLC | $14.19 | 1 |
Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMEETH VEDRE
NPI 1578643474 · CMS profile ID 117185
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
JACKSONVILLE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578643474?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMEETH VEDRE, NPI 1578643474, CMS profile ID 117185. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578643474?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). AMEETH VEDRE, NPI 1578643474, CMS profile ID 117185. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578643474?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- AMEETH VEDRE, NPI 1578643474, CMS profile ID 117185, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578643474?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
74 matching records · $1,598.59 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–74 of 74.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $8.49 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132051862 | CMS |
| SANOFI-AVENTIS U.S. LLC | $14.19 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139744438 | CMS |
| PFIZER INC. | $63.54 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131712682 | CMS |
| Lexicon Pharmaceuticals, Inc. | $16.88 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1081720347 | CMS |
| Merck Sharp & Dohme LLC | $102.00 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141872931 | CMS |
| Amgen Inc. | $23.56 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117708594 | CMS |
| Amgen Inc. | $7.50 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111732625 | CMS |
| Philips North America LLC | $28.33 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146870358 | CMS |
| Novo Nordisk Inc | $20.05 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096671124 | CMS |
| Merck Sharp & Dohme LLC | $15.62 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141930937 | CMS |
| PFIZER INC. | $14.25 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131712491 | CMS |
| Amgen Inc. | $21.54 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111732623 | CMS |
| Novartis Pharmaceuticals Corporation | $14.61 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087386424 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.70 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104416247 | CMS |
| Novartis Pharmaceuticals Corporation | $17.48 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087386426 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.15 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101449697 | CMS |
| Merck Sharp & Dohme LLC | $19.91 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141712035 | CMS |
| Novartis Pharmaceuticals Corporation | $14.93 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087386422 | CMS |
| Amgen Inc. | $18.42 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111732621 | CMS |
| Alnylam Pharmaceuticals Inc. | $18.39 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125840713 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.94 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104785694 | CMS |
| Merck Sharp & Dohme LLC | $18.58 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141712037 | CMS |
| Novartis Pharmaceuticals Corporation | $21.92 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087386420 | CMS |
| Kiniksa Pharmaceuticals International, plc | $16.15 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154887141 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $262,544.92 | 38 |
| PY2024 | Principal investigator | $230,774.18 | 7 |
| PY2023 | Principal investigator | $75,580.32 | 6 |
| PY2022 | Principal investigator | $43,945.77 | 4 |
| PY2021 | Principal investigator | $37,421.15 | 55 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
38 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension | No dispute reported | 06/30/2026 | 1190306341 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $460.00 | 11/24/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246790638 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $69,360.10 | 11/19/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190306337 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,750.00 | 10/31/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,000.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,618.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,250.00 | 10/28/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643973 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $575.00 | 10/14/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789220 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,700.00 | 10/14/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789224 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,725.00 | 10/14/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789229 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $8,250.00 | 10/14/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789234 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $15,000.00 | 10/14/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789239 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $58,211.08 | 10/14/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246789243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,016.00 | 10/02/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 10/02/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643969 |
| Principal investigator 1 | Verona Pharma, Inc. | $3,779.60 | 09/26/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINIC | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) | No dispute reported | 06/30/2026 | 1232891711 |
| Principal investigator 1 | Verona Pharma, Inc. | $252.00 | 09/26/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINIC | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) | No dispute reported | 06/30/2026 | 1232891713 |
| Principal investigator 1 | Verona Pharma, Inc. | $252.00 | 09/26/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINIC | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) | No dispute reported | 06/30/2026 | 1232891717 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,550.00 | 09/24/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEA | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185543112 |
| Principal investigator 1 | Verona Pharma, Inc. | $5,547.60 | 08/27/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINIC | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) | No dispute reported | 06/30/2026 | 1232891709 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $920.00 | 08/05/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246785994 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $920.00 | 08/05/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246786003 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,747.80 | 08/01/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINIC | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) | No dispute reported | 06/30/2026 | 1232891707 |
| Principal investigator 1 | Verona Pharma, Inc. | $750.00 | 08/01/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINIC | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) | No dispute reported | 06/30/2026 | 1232891715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $54.00 | 07/27/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 05/27/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 05/27/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 05/27/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220643949 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 05/13/2025 | Non-covered Recipient Entity First Coast Heart And Vascular Center | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220995076 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,625.00 | 03/17/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure | No dispute reported | 06/30/2026 | 1190300441 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $25,923.66 | 02/27/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190300431 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $450.00 | 02/27/2025 | Non-covered Recipient Entity JACKSONVILLE CENTER FOR CLINICAL RESEARCH | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension | No dispute reported | 06/30/2026 | 1190300445 |